Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
Date:5/23/2008

CALGARY, May 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced it has been granted Canadian Patent 2,360,833 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims describe the use of one or more recombinant reoviruses to treat Ras-mediated proliferative disorders.

"This patent provides the Company with additional patent protection for the use of reovirus compositions for cancers and other cellular proliferative disorders in Canada," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics please visit http://www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials,
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R)
2. Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent
3. Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting
4. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
7. Oncolytics Biotech Inc. Announces 2008 First Quarter Results
8. Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
9. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
10. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting
11. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... UK (PRWEB) , ... July 27, 2015 , ... Production ... growth over the past few years in the EU. For instance, it surpassed the ... the EUR 92 million mark in 2010. Germany is a major producer, while Italy ...
(Date:7/27/2015)...   Inocucor Technologies Inc ., the agriculture ... farmers, has received a notice of allowance from ... patent application to protect Inocucor consortia and unique ... yields on farms and in greenhouses. ... microbial consortium and its fermentation byproducts, which are ...
(Date:7/27/2015)... ... 27, 2015 , ... BlueInGreen® announced the addition of EnviroSales ... the world’s most efficient gas dissolution technology to all of Florida, excluding the ... industrial and municipal markets. With offices located in Sarasota, Sebring and Melbourne Beach, ...
(Date:7/27/2015)... , July 27, 2015 The ... announced the winners of its annual Klerman and ... by scientists who have been supported by NARSAD ... scientists to pursue innovative ideas in neurobiological and ... of concept for the early detection, treatment, prevention ...
Breaking Biology Technology:High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3BlueInGreen Brings Water Treatment Technology to Florida 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... Advocacy Groups Launch Joint Effort to Preserve Eyesight of,Millions At-Risk ... that eye exams are being,ignored by many aged over 40. ... the last year to have their eyes checked, even though,twice ... or early,death. The survey showed that awareness of glaucoma was ...
... CRVL ), a leading provider of workers, ... 150,000 facility and,provider locations to its national CorCare ... provider network additions are the,result of a new ... Petersburg, FL. With more than 5,500 hospitals ...
... Time-Saving, ATLANTA, Oct. 1 Harmonex ... a revolutionary software platform,designed to assess children, ... CliniCom(TM), an intuitive, computer assisted intake and ... settings, gathers information,directly from patients and their ...
Cached Biology Technology:International Survey Shows People Over Forty Ignore Risk of Blindness 2International Survey Shows People Over Forty Ignore Risk of Blindness 3International Survey Shows People Over Forty Ignore Risk of Blindness 4International Survey Shows People Over Forty Ignore Risk of Blindness 5CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care 2CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care 3Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 2Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 3
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... a prevalent fungal pathogen that causes 10,000 deaths per ... antifungal drugs by duplicating a section of one of ... yeast present in 80 percent of humans, is usually ... oral and vaginal infections (candiasis or thrush) that are ...
... at the Stanford University School of Medicine have taken ... cells that could eventually be transplanted into living organisms. ... surgical resident Oscar Abilez, MD, and colleagues have successfully ... building blocks of blood vessels, after placing them in ...
... technique of distraction has been researched and successfully applied ... with certain medical procedures. The use of distraction is ... psychological element in the perception of pain, with the ... the perception of the pain. , Distraction techniques ...
Cached Biology News:U of M researchers discover genetic key to treating deadly fungal infections 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 3Virtual realities against pain 2
Sphingosine 1-phosphate receptor Edg-1...
Bag-1 (K-20)...
... atoms at the 3, 3', 4, and ... as an internal standard for the quantification ... LC-mass spectrometry. PGE2 is one of the ... one of the most widely investigated prostaglandins. ...
, Glycerol 30%...
Biology Products: